DALLAS - TelAve -- ClearSight Therapeutics Signs Letter of Intent with Covalent Medical to Expand         OTC Eye Care Portfolio Through Multi-Channel Commercial Partnership

DALLAS, TX — [February 24, 2026] — ClearSight Therapeutics, Inc., an innovator in over-the-counter ophthalmic solutions, today announced the signing of a non-binding Letter of Intent (LOI) with Covalent Medical, LLC to establish a private-label manufacturing and supply partnership for ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye Products.

Under the proposed partnership, Covalent Medical intends to commercialize ClearSight's portfolio through both physician-dispensed and retail channels. The products will be introduced under Covalent's existing professional brand, Focus Tears, distributed directly through eye care practices nationwide, as well as under a new retail-focused brand targeting major national retailers.

Illustrative projections included in the LOI outline a potential five-year commercial relationship valued at approximately $60 million, reflecting anticipated product volumes across both clinical and retail markets.

The parties are currently negotiating definitive terms, with initial commercial launch anticipated in Q1 2027.

More on TelAve News

• Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE
• Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
• The Franchise King® Releases Free Guide for Nervous Buyers
• Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
• CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs

"This agreement represents a significant milestone for ClearSight and validates both our product portfolio and manufacturing platform," said Patrick Smale, CEO of ClearSight Therapeutics. "Covalent's leadership, commercial infrastructure, and deep relationships across eye care providers and retail partners position them to accelerate market adoption of our OTC ophthalmic solutions."

Clint Worley, COO of Covalent Medical, added, "ClearSight's portfolio aligns closely with our strategy to expand across both professional and consumer channels. Their manufacturing expertise and regulatory foundation provide an ideal platform for building differentiated eye care brands."

Bob Zatarain, Head of Sales and Business Development and Board Member at Covalent Medical, commented, "Having spent over two decades in the ophthalmic industry, I recognize the importance of delivering accessible, high-quality OTC solutions. This partnership strengthens Covalent's ability to serve both practitioners and patients with innovative, compliant products."

Dr. Kairy Barazi, Founder and CEO of Covalent Medical, added, "Our focus has always been on identifying clinically grounded solutions that meet real patient needs. ClearSight's approach to product development and quality aligns well with our long-term vision for expanding access to modern eye care."

Under the proposed structure, ClearSight will retain responsibility for manufacturing, quality assurance, and regulatory compliance, while Covalent will oversee branding, packaging, and commercialization across designated channels.

More on TelAve News

• NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
• Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
• Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
• Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
• Author Ken Mora to Celebrate New Caravaggio Book Debut with Special Event at Palazzo Venezia Naples

The companies intend to finalize a definitive agreement later this year, with commercialization targeted for 2027.

About ClearSight Therapeutics

Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. With a patient-first approach, the company is dedicated to making OTC eye care products that are safe, effective, and accessible to all.  For more information visit www.clearsighttx.com.

About Covalent Medical

Covalent Medical, LLC was formed by over 400 retina specialists in 2011 and is one of the largest commercial organization of retina specialists in the country.  Covalent Medical, which owns the brands name Focus Vitamins and SightGuardian, is a patient-focused company that produces research-based eye vitamins and OTC products with a focus on quality and safety, and are sold directly through eyecare professionals, on-line retailers, and on their website.  For more information, visit www.focusvitamins.com.

# # #

Media Contact(s):

ClearSight - Patrick Smale, CEO

972-983-7761

patrick@clearsighttx.com

Covalent Medical – Clint Worley, COO

703-832-5869

cworley@focusvitamins.com